Macrophages in intestinal homeostasis and inflammation.

Bain CC, Mowat AM. · 2014

Read Macrophages in intestinal homeostasis and inflammation. by Bain CC, Mowat AM. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4141699.txt.

Introduction

Calum C. Bain and Allan McI. Mowat reviewed macrophages in the intestine, the body's largest pool of these immune cells. Their review appeared in Immunological Reviews in 2014. Gut macrophages keep peace with resident microbes and renewing tissue, yet they also fight infection and drive inflammatory bowel disease.

Sorting out their jobs was long hampered by the difficulty of telling similar cell populations apart. The authors explain how combined markers separate functionally distinct groups. Unlike most tissue macrophages, gut macrophages break the self-renewing embryo-derived pattern: blood monocytes constantly enter the mucosa and the local environment decides what they become. Knowing what drives their development in calm and inflamed states could open treatments, they argue.

Catalog record

CREATORBain CC, Mowat AM.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE84 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4141699

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Macrophages in intestinal homeostasis and inflammation By Calum C Bain, Allan McI Mowat Published in: Immunological Reviews DOI: 10.1111/imr.12192 ABSTRACT The intestine contains the largest pool of macrophages in the body which are essential for maintaining mucosal homeostasis in the face of the microbiota and the constant need for epithelial renewal but are also important components of protective immunity and are involved in the pathology of inflammatory bowel disease (IBD). However, defining the biological roles of intestinal macrophages has been impeded by problems in defining the phenotype and origins of different populations of myeloid cells in the mucosa. Here, we discuss how multiple parameters can be used in combination to discriminate between functionally distinct myeloid cells and discuss the roles of macrophages during homeostasis and how these may change when inflammation ensues. We also discuss the evidence that intestinal macrophages do not fit the current paradigm that tissue-resident macrophages are derived from embryonic precursors that self-renew in situ, but require constant replenishment by blood monocytes. We describe our recent work demonstrating that classical monocytes constantly enter the intestinal mucosa and how the environment dictates their subsequent fate. We believe that understanding the factors that drive intestinal macrophage development in the steady state and how these may change in response to pathogens or inflammation could provide important insights into the treatment of IBD. "This article is part of a series of reviews covering Mucosal Immunity appearing in Volume 260 of Immunological Reviews." INTRODUCTION As discussed elsewhere in this volume, the intestine is the largest mucosal surface of the body and is the single biggest compartment of the immune system. It is exposed constantly to an array of foreign antigens and must discriminate between harmful and harmless antigens to ensure that the appropriate response is mounted to each. Robust protective immune responses must be generated in response to pathogenic insult, but similar responses mounted against innocuous dietary proteins or commensal bacteria can lead to the development of chronic inflammatory disorders such as celiac disease and Crohn's disease, respectively. Mononuclear phagocytes (MPs) comprising both macrophages (mϕ) and dendritic cells (DCs) are central to this discrimination process and therefore hold promise as targets for potential novel therapies to treat IBD. In this article, we discuss the role of mϕ in gut homeostasis and describe how they change when inflammation or infection is present. Furthermore, we discuss the ontogeny of intestinal mϕ and highlight that unlike many other tissue mϕ, those resident in the gut wall must be replenished continually by blood monocytes, whose fate is ultimately dictated by the environment into which they arrive. These unusual mϕ are ideally adapted to their surroundings and raise many questions about current views of the MP system and its functions. THE CHALLENGES OF IDENTIFYING INTESTINAL MACROPHAGES MPs are one of the most abundant populations of leukocytes in the healthy intestinal mucosa, and this is the largest population of mϕ in the body 1,2. However, our understanding of the roles that individual subsets of DCs and macrophages play in maintaining homeostasis, and how they change when protective immune responses or inflammation occur has been stifled by the inability to identify these cells accurately. In large part, this is due to the substantial overlap in surface phenotype of intestinal DCs, mϕ, and other myeloid cells in the mucosa. For instance, although DCs in mice are traditionally identified by their co-expression of CD11c and major histocompatibility complex class II (MHCII), it is clear that mϕ of the gut wall express both these markers at high levels 3. Furthermore, CD11c has been shown to be expressed by plasma cells 4 and intestinal eosinophils in mice 5,6, with the latter also expressing the pan- mϕ marker F4/80 7,8. Expression of the fractalkine receptor CX3CR1 has also been used extensively to distinguish murine DCs from mϕ, with the proposal that these cells exhibited mutually exclusive expression of CD103, the αE integrin, and CX3CR1, respectively 9–11. However, it is now clear that both mϕ and some DCs can express CX3CR1, albeit at different levels, while not all bona fide mucosal DCs are CD103+ 12–14. Thus, many of the surface markers regarded as ‘lineage-specific’ are now known to be expressed by multiple cell types, which in the past has led to the mischaracterization of mucosal MP. Some studies still use CD11c and MHCII co-expression alone to identify DC in non-lymphoid tissues, which makes the interpretation of these studies complex 15. Therefore, it is clear that unambiguous identification of intestinal mϕ and DC requires thorough multi-parameter analysis, with several surface markers needing to be examined in combination. A useful approach to this comes from recent work that has demonstrated that expression of CD64 (the high affinity FcRγ1), F4/80 and MerTK 12,16,17, can be used in combination with CD11c and MHCII to define functionally distinct MP populations in mice. In the intestine, we have shown that CD11c+ MHCII+ MPs expressing CD64 and/or F4/80 are highly phagocytic cells with abundant foamy cytoplasm 12. These cells do not migrate to the mesenteric lymph nodes (MLNs) 13,14, cannot prime naive T cells 14, and their development in vivo requires the CSF-1R 18,19, but not the DC-specific growth factor flt3 ligand (flt3L) 12,13,16. Together, these features confirm the classification of CD64+ MPs as mϕ. When identified appropriately, murine intestinal mϕ can be shown to express a number of characteristic surface molecules in addition to F4/80 and CD64, including the hemoglobin scavenger receptor CD163 and the mannose receptor (CD206) 12. Mature intestinal mϕ also express high levels of CX3CR1, although as discussed below, this appears to be acquired during local differentiation in situ and some cells of the mϕ lineage express lower levels of CX3CR1 12. It is important to note that CX3CR1 expression is not a characteristic shared by all tissue mϕ. For instance, lung alveolar mϕ, splenic red pulp mϕ, liver Kupffer cells, epidermal Langerhans cells, and mϕ of the peritoneal cavity all lack CX3CR1 expression 20, although fate mapping studies suggest they derive from a CX3CR1-expressing progenitor 20. Retention and/or upregulation of CX3CR1 expression only occurs in some mϕ. As well as those in the intestine, this includes microglia of the CNS and mϕ resident in the kidney 20. It seems likely that this is driven by signals from the environment (see below). In contrast, CD64− F4/80− CD11c+ MHCII+ MPs display poor phagocytic activity, expand markedly in response to exogenous flt3L administration, and express the DC-specific transcription factor Zbtb46 12,13,21. As these CD64− F4/80− MPs also migrate constitutively to the MLNs in a CCR7-dependent manner and excel at priming naive T cells 13,14, they appear to represent classical migratory DCs. As discussed in more detail by Agace and colleagues elsewhere in this volume, it is important to mention that the intestinal DC compartment is itself heterogeneous, with discrete subsets identifiable on the basis of CD103 and CD11b expression 13,21,22. Although it was once thought that all mucosal DC expressed CD103, it is now clear that bona fide CD103− DCs exist 13,21 and that CD103 cannot be used as a de facto marker of mucosal DCs. Importantly, CD103− CD11b+ DCs also express intermediate levels of CX3CR1, making them almost identical to mϕ in terms of their surface phenotype. This emphasizes

Read the complete text